Coherus Oncology, Inc.CHRSNASDAQ
Loading
EV to Sales: Discounted ValuationCompressed
Percentile Rank31
3Y CAGR-12.9%
5Y CAGR+6.6%
Year-over-Year Change
Enterprise value to sales ratio
3Y CAGR
-12.9%/yr
vs -66.7%/yr prior
5Y CAGR
+6.6%/yr
Recent deceleration
Acceleration
+53.8pp
Accelerating
Percentile
P31
Within normal range
vs 5Y Ago
1.4x
Solid growth
Streak
1 yr
Consecutive growthCompressed
| Period | Value | YoY Change |
|---|---|---|
| 2025 | 3.23 | +185.9% |
| 2024 | 1.13 | -57.9% |
| 2023 | 2.69 | -45.0% |
| 2022 | 4.89 | +32.4% |
| 2021 | 3.69 | +57.3% |
| 2020 | 2.35 | -33.9% |
| 2019 | 3.55 | -99.1% |
| 2018 | 397.88 | +40.0% |
| 2017 | 284.11 | +4575.7% |
| 2016 | 6.08 | - |